289 related articles for article (PubMed ID: 30575819)
1. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
2. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS
Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
4. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
5. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
7. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.
Sarhan D; Wang J; Sunil Arvindam U; Hallstrom C; Verneris MR; Grzywacz B; Warlick E; Blazar BR; Miller JS
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32045384
[TBL] [Abstract][Full Text] [Related]
9. Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.
Roversi FM; Lopes MR; Machado-Neto JA; Longhini AL; Duarte Ada S; Baratti MO; Palodetto B; Corrocher FA; Pericole FV; Campos Pde M; Favaro P; Traina F; Saad ST
Stem Cells Dev; 2014 May; 23(10):1109-20. PubMed ID: 24410667
[TBL] [Abstract][Full Text] [Related]
10. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.
Zhao ZG; Xu W; Yu HP; Fang BL; Wu SH; Li F; Li WM; Li QB; Chen ZC; Zou P
Cancer Lett; 2012 Apr; 317(2):136-43. PubMed ID: 22240014
[TBL] [Abstract][Full Text] [Related]
11. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.
Bhagat TD; Chen S; Bartenstein M; Barlowe AT; Von Ahrens D; Choudhary GS; Tivnan P; Amin E; Marcondes AM; Sanders MA; Hoogenboezem RM; Kambhampati S; Ramachandra N; Mantzaris I; Sukrithan V; Laurence R; Lopez R; Bhagat P; Giricz O; Sohal D; Wickrema A; Yeung C; Gritsman K; Aplan P; Hochedlinger K; Yu Y; Pradhan K; Zhang J; Greally JM; Mukherjee S; Pellagatti A; Boultwood J; Will B; Steidl U; Raaijmakers MHGP; Deeg HJ; Kharas MG; Verma A
Cancer Res; 2017 Sep; 77(18):4846-4857. PubMed ID: 28684528
[TBL] [Abstract][Full Text] [Related]
12. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
Yang Y; Li J; Geng Y; Liu L; Li D
J Clin Lab Anal; 2021 Feb; 35(2):e23597. PubMed ID: 33080073
[TBL] [Abstract][Full Text] [Related]
14. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.
Fei C; Zhao Y; Guo J; Gu S; Li X; Chang C
Eur J Haematol; 2014 Dec; 93(6):476-86. PubMed ID: 24889123
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.
Medyouf H; Mossner M; Jann JC; Nolte F; Raffel S; Herrmann C; Lier A; Eisen C; Nowak V; Zens B; Müdder K; Klein C; Obländer J; Fey S; Vogler J; Fabarius A; Riedl E; Roehl H; Kohlmann A; Staller M; Haferlach C; Müller N; John T; Platzbecker U; Metzgeroth G; Hofmann WK; Trumpp A; Nowak D
Cell Stem Cell; 2014 Jun; 14(6):824-37. PubMed ID: 24704494
[TBL] [Abstract][Full Text] [Related]
16. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
Gill H
Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.
Borriello L; Nakata R; Sheard MA; Fernandez GE; Sposto R; Malvar J; Blavier L; Shimada H; Asgharzadeh S; Seeger RC; DeClerck YA
Cancer Res; 2017 Sep; 77(18):5142-5157. PubMed ID: 28687621
[TBL] [Abstract][Full Text] [Related]
18. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
[TBL] [Abstract][Full Text] [Related]
20. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
